Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 1998 Feb 16;187(4):461–468. doi: 10.1084/jem.187.4.461

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Effects of antibody treatment on arthritis index of CII-immunized DBA/1J mice. (A) Mice (n = 9 for each group) were treated once per week with 1 mg/mouse (white symbols) or 0.5 mg/mouse (black symbols) of either anti–IL-6Rα antibody 15A7 (circles), anti–dinitrophenyl hapten antibody LO-DNP (triangles), or left untreated (squares). *P <0.05 either 15A7 or LO-DNP versus none. (B) Mice were treated with 1 mg/ wk/mouse of either anti–IL6-Rα antibody 15A7 (circles; n = 9), rat total IgG antibodies (diamonds; n = 8), or left untreated (squares; n = 8). *P < 0.02 15A7 versus none; ^# P <0.04 total IgG versus none. Results were reported as mean ± SD. The weeks after the first immunization with CII and the duration of antibody treatment are indicated on the abscissa.

HHS Vulnerability Disclosure